Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

Time to first cigarette independently predicts lung cancer

The time to first cigarette after waking is an independent risk factor for lung cancer, a Japanese case-control study has found.

27 Sep 2013

New class of antidepressants appears potentially effective in combating deadly form of lung cancer

A little-used class of antidepressants appears potentially effective in combating a particularly deadly form of lung cancer, according to a new study from researchers at the Stanford University School of Medicine.

27 Sep 2013

miR-31 in primary tumor cells predicts lymph node metastasis in NSCLC patients

Determining whether a patient's lung cancer has spread to nearby lymph nodes is critical for identifying the most effective therapy, but it usually requires surgery. A new study suggests, however, that measuring levels of a particular molecule in a sample of tumor tissue might accurately answer the question.

25 Sep 2013

Protein pair may be prognostic biomarker for identifying smoking-related lung cancers

Mayo Clinic researchers have shown that a specific protein pair may be a successful prognostic biomarker for identifying smoking-related lung cancers. The protein — ASCL1 — is associated with increased expression of the RET oncogene, a particular cancer-causing gene called RET. The findings appear in the online issue of the journal Oncogene.

20 Sep 2013

Study reports identification of IDH1 protein as novel biomarker for diagnosis of NSCLC

A protein called isocitrate dehydrogenase is present at high levels in lung cancers and can be detected in the blood, making it a noninvasive diagnostic marker for lung cancers, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

17 Sep 2013

GGO-dominant lung tumors have excellent prognosis

Ground glass opacity-dominant clinical stage IA lung adenocarcinoma is a low-grade malignancy with an “excellent” prognosis, Japanese researchers believe.

10 Sep 2013

FDA approves ABRAXANE chemotherapy drug for treatment of metastatic pancreatic cancer

The Pancreatic Cancer Action Network is pleased to announce that today ABRAXANE® was approved by the U.S. Food and Drug Administration (FDA) to treat metastatic pancreatic cancer.

7 Sep 2013

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute.

7 Sep 2013

Assay aids ALK fusion detection in lung adenonocarcinoma

A fully automated immunochemistry assay is highly sensitive and specific for detecting anaplastic lymphoma kinase fusion in primary lung adenocarcinomas, Chinese researchers report.

6 Sep 2013

Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC

Albumin-bound paclitaxel plus carboplatin is an effective and well-tolerated first-line treatment in patients with advanced non-small-cell lung cancer, irrespective of histology, study results show.

29 Aug 2013

Study compares spectrum of cancer-related gene mutations in two common types of cervical cancer

A new study has revealed marked differences in the genomic terrain of the two most common types of cervical cancer, suggesting that patients might benefit from therapies geared to each type's molecular idiosyncrasies.

26 Aug 2013

Seven researchers to receive grants from ASTRO to advance radiation oncology research

The American Society for Radiation Oncology (ASTRO) has selected seven (7) leading researchers who will receive a total of $675,000 in awards and grants to advance radiation oncology research.

23 Aug 2013

High mobility group (HMG) genes and cancer: an interview with Dr. Linda Resar, Johns Hopkins University School of Medicine

High mobility group A genes are highly expressed in all aggressive cancers studied to date. These genes encode the high mobility group A (HMGA) proteins. In other words, these genes provide the genetic “code” necessary to produce HMGA proteins.

8 Aug 2013

Specific pattern in lung tumor pathology is strong predictor of recurrence, says study

A new study by thoracic surgeons and pathologists at Memorial Sloan-Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence.

8 Aug 2013

Study reveals nearly 40% of tumors are caused by viruses

The results of a large-scale analysis of the association between DNA viruses and human malignancies suggest that many of the most common cancers are not associated with DNA viruses.

6 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

Research team receives NCI grant to develop precision therapies that kill cancer cells

A research team headed by Fred Hutchinson Cancer Research Center scientists Christopher Kemp, Ph.D., and Carla Grandori, M.D., Ph.D., has received a $4 million grant from the National Cancer Institute to develop precision therapies that selectively kill cancer cells while sparing normal, healthy tissue.

24 Jul 2013

Scientists develop histology expression predictor for most common types of lung cancer

Knowing what type of lung cancer a patient has is critical to determine which drug will work best and which therapies are safest in the era of personalized medicine. Key to making that judgment is an adequate tumor specimen for the pathologist to determine the tumor's histology, a molecular description of a tumor based on the appearance of cells under a microscope.

17 Jul 2013

Aflibercept drug shows minor added benefit for overall survival in colorectal cancer patients

The drug aflibercept (trade name: Zaltrap) has been approved in Germany since February 2013 in combination with a certain chemotherapy for adults with metastatic colorectal cancer in whom chemotherapy with oxaliplatin could not stop the disease from progressing.

12 Jul 2013

Prolonged exposure to low levels of air pollution boosts lung cancer risk

Prolonged exposure to particulate air pollution increases the risk of lung cancer (particularly adenocarcinoma) even at levels below the European Union limit values, according to one of the largest studies of its kind published in The Lancet Oncology.

11 Jul 2013